Stockreport

Reassessing Astellas Pharma (TSE:4503) Valuation After Positive PADCEV-Keytruda Phase 3 Bladder Cancer Results [Yahoo! Finance]

ASTELLAS PHARMA UNSP/ADR  (ALPMY) 
NASDAQ:AMEX Investor Relations: astellas.com/jp/en/investors
PDF endpoints in a Phase 3 bladder cancer trial, sharpening the stock's long term growth story. See our latest analysis for Astellas Pharma. The market has been warming [Read more]